Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00070837 (Clinical Trial / MLN-2704)

Study Title
MLN-2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer (NCT00070837)

Trial Description
The purpose of the study is to determine the highest dose of MLN-2704, also known as MLN 591-DM1, that can be given multiple times safely to patients with prostate cancer, and to identify any side effects associated with taking the drug. This study will also evaluate how MLN2704 is taken up, broken down and eliminated by the body.

This trial is sponsored by Millennium Pharmaceuticals. [1]

Study Data

  • Condition: Prostatic Neoplasms
  • Interventions:
    • Drugs used in this trial
      • MLN-2704 (MLN 591-DM1)
  • Phase: I & II
  • Estimated Enrollment: 46
  • Start: October 2003
  • Estimated Completion: October 2004
  • Last verified: July 2007

Study Schematic 

(Coming soon)

Click here to Return to Drug map


Last Editorial review: August 10, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar